Terminated PHASE2 INTERVENTIONAL 1-arm NCT00830245

A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

Sponsor: Clinical Research Center for Solid Tumor, Korea

Conditions Leptomeningeal Carcinomatosis Non-small Cell Lung Cancer

Interventions Erlotinib

Updated 6 times since 2017 Last updated: Jul 25, 2011 Started: Jan 31, 2009 Primary completion: Jul 31, 2011 Completion: Jul 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

low accrual rate

A PHASE2 clinical study on Leptomeningeal Carcinomatosis and Non-small Cell Lung Cancer, this trial is terminated or withdrawn. The trial is conducted by Clinical Research Center for Solid Tumor, Korea and has accumulated 6 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clinical Research Center for Solid Tumor, Korea
Korean Cancer Study Group
Seoul National University Hospital

Data source: Clinical Research Center for Solid Tumor, Korea

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea